

Microbiota: A Key for Healthy Aging

Yoon Jin Choi¹, Dong Ho Lee^{1,2}

¹Department of Internal Medicine and Seoul National University Bundang Hospital, Seongnam, ²Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

Corresponding Author:
Dong Ho Lee, MD, PhD
Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 beon-gil, Bundang-gu, Seongnam 13620, Korea

Tel: +82-31-787-7008
Fax: +82-31-787-4051
E-mail: dhjohn@yahoo.com

Received: October 24, 2016
Revised: October 26, 2016
Accepted: December 16, 2016

A growing body of literature has suggested that changes in the composition of gut microbiota could be associated with age-related processes. Significant changes in the gastrointestinal microbiota in the elderly have been reported according to diet, drug use, and place of residence. Moreover, changes in microbiota composition in old age have been associated with immunosenescence and inflammatory processes that are pathophysiological mechanisms involved in frailty. A better understanding of the possible reasons for changes in gut microbiota in the elderly and the impact of these changes on health could be a basis for maintaining healthy gut function and healthy aging in the present situation with an increasing elderly population.

Key Words: Microbiota, Bifidobacterium, Aging, Frailty, Elderly

INTRODUCTION

Healthy aging is going to become an important issue, since the development of medicine has achieved unprecedented longevity leading to a skyrocketing proportion of the global population over 65 years of age. In Korea, the proportion of those older than 65 years is projected to increase from 13.1% in 2015 to 40.1% in 2060¹⁾. An increasing elderly population directly leads to a mounting socioeconomic burden because those within this age range have great susceptibility to age-related diseases and disabilities such as infection, musculoskeletal disease, malignancy, and degenerative brain diseases. For this reason, strategies need to be changed from treatment of disease to preventing or delaying age-related diseases and maintaining good health as long as possible to reduce the duration and severity of morbidity that precedes death.

Consumption of a nutritionally balanced diet and maintaining a healthy lifestyle have been the basis for healthy aging, and a growing body of evidence supports that the intestinal microbiota is closely linked to human health²⁻⁴⁾. The gut provides the largest physical interface between the environment, including pathogen, and the host itself. Metagenomic and metabolomic methods are becoming more prevalent, making it possible to more comprehensively examine the composition and functionality of the intestinal microbiota related to dis-

eases or aging⁵⁾.

In this review, we aim to briefly summarize the process of the establishment of the gut microbiota and the evidence of the impact of aging on the intestinal microbiota composition, with particular attention to potential common pathological conditions in the elderly. Subsequently we discuss the potential reasons for changes in the gastrointestinal (GI) microbiota profile, and review the probiotics focused on the age-related condition to find a clue for delaying age-dependent deterioration of the microbiota-host symbiotic relationship. The pathogenesis of specific disorders that could be associated with dysbiosis in the elderly will be included in the review to provide a hint of the potential applications and future perspectives of this field of research.

ESTABLISHMENT OF GUT MICROBIOTA

"Gut microbes are our life-long companions: they live inside us, the vast majority of them within our GI tract, in a complex and dynamic mutualistic relationship starting from our very first days of life."⁶⁾ During delivery, the infant gut is colonized by microbes of maternal, dietary, and environmental origin. The presence of microorganisms in the placenta or amniotic fluid⁷⁾ suggests a primary fetal colonization. Beginning in early infancy, interaction with these environmental microbes is pivotal for the development of the intestinal mucosa and the maturation of the human immune

FOETUS	BABY	CHILD	ADULTS	ELDERLY	
Usually sterile	Breast-fed-bifidobacteria usually dominate Bottle fed-more diverse with more Bacteroidetes, and less bifidobacteria	Increase in microbial diversity following weaning and intake of solids	Dominant phyla Firmicutes Bacteroidetes Actinobacteria	Less dominant phyla Proteobacteria Verrucomicrobia	Compared to healthy adults- Reduction in Firmicutes and bifidobacteria Increase in Bacteroidetes and Proteobacteria

Fig. 1. Schematic summarizing changes in the composition of the gut microbiota through different life stages. Adapted from Duncan et al. *Maturitas* 2013;75:44-50¹⁸⁾.

system⁸⁾. At weaning, the GI ecosystem is stabilized toward an adult-type phylogenetic architecture^{9,10)}. Actinobacteria, followed by Proteobacteria and Firmicutes are the main phyla in early childhood, characterized by low diversity and complexity^{9,11)}. The main changes in gut microbiota composition take place in the first stage of life, getting to a relative stability at 1–2 years old¹²⁾. The adult-like structure of the gut microbiota is thought to occur after the third year of life^{9,13)} and reaches a total number of 10¹⁴⁾ microorganisms comprising bacteria, eukaryotes, viruses, and archaeal members^{14,15)}. At the phylum level, the gut microbiota is made up of 80%–90% Firmicutes and Bacteroidetes. At the species and strain taxonomic level, the diversity is very high in adults and is characterized by high inter-individual variability¹⁴⁾. However, the functionality and metabolism of the gut microbiota is highly conserved³⁾. The GI microbiota of a healthy adult has been regarded as relatively stable throughout adulthood, until aging and aging-related pathophysiological processes start to affect its homeostasis^{16,17)}. A schematic summary of the changes in the composition of the gut microbiota during a lifetime is illustrated in Fig. 1. Many of these commensals are essential to our health, helping to digest carbohydrates and create energy-rich short-chain fatty acids (SCFAs), synthesizing vitamins, and metabolizing toxins.

CHANGE OF GUT MICROBIOTA IN THE ELDERLY

Large interindividual variability in the microbiota, even in elderly subjects, and the reduced diversity of the intestinal microbiota in the elderly compared with younger individuals have been relatively uniformly reported^{17,19)}.

Despite the downregulated microbial diversity, it has been accepted that Bacteroidetes and Firmicutes still constitute the dominant phyla in elderly, with lower contributions from the Actinobacteria and Proteobacteria phyla^{17,20)}. Nonetheless, the current knowledge of the age-related changes in the ratio of Firmicutes to Bacteroidetes is somewhat controversial, with results varying according to nationality and age of the enrolled subjects¹⁷⁾.

Regarding Firmicutes, members of the *Clostridium* cluster XIVa (a dominant group in the intestinal microbiota), which

produces SCFAs, were found to decrease in elderly Japanese, Finnish, and Italian subjects, including centenarians^{17,21-23)}, whereas an inverse trend was found in elderly German adults²³⁾. The species *Faecalibacterium prausnitzii*, which belongs to the *Clostridium* cluster IV and produces SCFAs, was significantly decreased in elderly Italians, including centenarians^{16,23)}, although this result was not confirmed in other European populations^{23,24)}. A decrease in this important anti-inflammatory Firmicutes member of the gut microbiota has been relatively consistently reported in frail, hospitalized, antibiotic- and anti-inflammatory-treated elderly rather than in general elderly population²⁵⁻²⁸⁾.

Conversely, an age-related increase in Bacteroidetes was found in German, Austrian, Finnish, and Irish elderly^{22-24,27)}, but this was not confirmed in elderly Italians, including centenarians^{16,23)}. Intriguingly, in the case of the Irish elderly, Bacteroidetes were found to be the dominant phylum instead of Firmicutes, which has always been regarded as the most abundant in healthy adults²⁴⁾. Currently, there is no consensus regarding the old-age specific gut microbiota profile due to the high interindividual variability, differences in diet and lifestyle, the unclear definition of the term “elderly,” and different methodologies for stool sampling or analysis. However, some trends are repeatedly observed, such as the decrease of bifidobacteria, which is usually regarded as contributor to a health-favorable microbiome in the elderly population; this has been confirmed by several studies^{17,29,30)}. Unlike Firmicutes and Bacteroidetes, facultative anaerobes, including streptococci, staphylococci, enterococci, and enterobacteria^{16,22,23,31,32)}, which are able to thrive in inflamed conditions and nurture the inflammation itself³³⁾, are repeatedly shown to be increased in aged people.

Centenarians, extremely aged people, have microbiota still dominated by Bacteroidetes and Firmicutes (overall, 93% of total bacteria)³⁴⁾, but the results remain somewhat controversial. In a European population, the microbiota composition of centenarians was similar to that of adults¹⁶⁾. However, higher proportions of bifidobacteria were observed in centenarians than in younger elderly subjects from Guangxi in China³⁵⁾. Regarding species, *Bifidobacterium longum* was the most abundant in Italian centenarians followed by *Bifidobacterium adolescentis* and *Bifidobacterium bifidum*³⁶⁾, but *Bifido-*

bacterium dentium was dominant in Chinese centenarians³⁷. Different diets and regions could contribute to the different results.

POSSIBLE REASONS FOR THE CHANGE OF GUT MICROBIOTA IN THE ELDERLY

The mechanism of the change in the microbiota with age is not totally understood. Factors related to lifestyles of aged individuals including nutrition, mobility, and pathophysiologic change could lead to GI dysbiosis, which compromises the microbiota host mutualistic relationship.

Changes in taste³⁸ along with a reduced number of teeth and weakened chewing strength³⁹ strongly affects an elderly individual's diet⁴⁰, subsequently resulting in the intake of a limited range of nutrients to support microbial growth. Typically, the elderly decrease their intake of food containing fiber and proteins, such as vegetables and meat, and this is strongly correlated to changes in the phylogenetic and functional structure of the gut ecosystem^{41,42}. The relationship between food and the composition of the gut microbiota has been recently demonstrated⁴³. The microbiota of elderly people dwelling in residential care facilities was definitely different from that of the free-living elderly, even with the same ethnic and geographic conditions. The different dietary habits of the institutionalized elderly compared with the community-dwelling aged people can be associated with differences in the microbiota composition: the less diverse diet of long-stay residents resulted in a less diverse fecal microbiota profile. Both short-term and long-term dietary changes could affect the gut microbiota composition⁴⁴. This can be a selection of specific microbial groups that are able to harvest as much energy as possible from the available substrates³⁴.

Intestinal motility may decrease with age⁴⁵. This results in a longer transit time and alteration of the dynamics regarding nutrient turnover and consequently the microbiota profile.

Physiologic changes in the GI tract, as well as in other lifestyle components, may also influence the gut microbiota composition according to aging. Diminished physical activity compared with younger people also causes a reduced intestinal motility, which can lead to constipation, altered bacterial fermentation and metabolite production, and reduced bacterial excretion^{17,46}, possibly resulting in an excessive bacterial load challenge that is difficult to handle for an immunosenescent host^{46,47}.

Broad-spectrum antibiotic therapy or cocktail therapy with more than three antibiotics affects the entire GI microbiota^{48,49}. The consequences of an altered GI microbiota after antibiotic therapy include increased carriage of antibiotic resistance genes, susceptibility to diarrheic syndromes, enteric infection, and altered inflammatory responses^{50,51}. It has

been reported that antibiotic therapy reduces overall bacterial diversity, affecting up to 33% of the microbial population and that it can also have an individualized effect on the GI microbiota⁵². More recently, a study showed the impact of antibiotic therapy prescribed during the previous month on microbiota composition of 185 older subjects staying in different settings, that is, long-term and short-term care, outpatient service, or community dwelling⁵³. A significant decrease of *Bifidobacterium* spp. and a relative decrease of *Faecalibacterium* spp. was observed after use of nucleic acid synthesis inhibitors⁵³. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) may influence the composition of the GI microbiota. A significant reduction in the Firmicutes, particularly in *Clostridium* cluster XIVa, and in the *Actinobacteria* was observed in older NSAID users compared with older nonusers and young adults²². Proton pump inhibitors, which are usually prescribed to elderly NSAIDs users could change the composition of the GI microbiota, leading to a less healthy gut microbiome^{54,55}.

THE IMPACT OF CHANGES IN THE GI MICROBIOTA ON HEALTH IN OLD AGE

The changes in the phylogenetic architecture of the gut microbiota that accompany the aging process could affect various aspects of human function, including a decline in metabolic and physiological functions, the defense capacity against pathogens, and even central nervous system (CNS) function (Fig. 2). This disruption of homeostasis leads to increased vulnerability to many diseases with aging.

1. Infection and Dysmotility in the Intestines

A markedly reduced bacterial diversity has been associated with active *Clostridium difficile*-associated diarrhea (CDAD), a major nosocomial complication for the elderly in hospitals and long-term facilities^{56,57}. Since toxin-producing *C. difficile* species have also been detected in asymptomatic aged subjects, it has been assumed that a good commensal microbiota may play a protective role by preventing potentially pathogenic *C. difficile* from overcoming colonization resistance, proliferating, and producing toxins⁵⁷. Within this context is the aim of fecal microbiota transplantation, a promising intervention for CDAD for restoring a protective healthy gut microbiota⁵⁸.

The production of SCFAs such as butyrate, acetate, and propionate by several members of the microbiota^{59,60} is the essence of a healthy gut system.

Butyrate strongly stimulates the release of mucins that contribute to the physical separation between the microbiota and colonic cells^{61,62}. SCFAs also enhance transepithelial resistance both *in vitro* and in an animal model⁶³. Hippe et al.⁶⁴




Fig. 2. Impact of changes in the gut microbiota on health in the elderly. SCFA, short-chain fatty acid; ROS, reactive oxygen species.

demonstrated that the elderly had significantly fewer copies of the butyryl-CoA:acetate-CoA transferase gene than younger adults. This functional decline was correlated with decreased amounts of *F. prausnitzii*, *Eubacterium hallii*, and bacteria belonging to the *Eubacterium rectale*/*Roseburia* group, which are all butyrate producers and belong to the bacterial groups found in lower amounts in centenarians¹⁶. This age-related microbiota depletion in SCFA producers may concur in compromising the integrity of the epithelial barrier. Such a weakened gut epithelium allows the passage of whole bacterial cells and their products and compromises immunological tolerance⁶⁵. In particular, in the context of a weakened gut epithelium, the proliferation of Enterobacteriaceae and other gram-negative bacteria has been proposed to cause an excessive endotoxin challenge, leading to an abnormal inflammatory response⁶⁶.

The elderly consume less fiber than younger individuals owing to a declining sensation of taste and olfaction or reduced income. This results in a reduction in butyrate formation and an increased formation of a variety of deleterious metabolites.

The decrease in fiber intake in the elderly may also trigger gut dysmotility. Methane formed by methanogens, which are more abundant in the elderly¹⁵, can slow gut transit by influencing smooth muscle contractility⁶⁷, and conversely, high butyrate levels can result in an accelerated gut transit⁶⁸. Slow bowel transit in the elderly will also affect the metabolic products in the colon and increase colonic pH compared with that in younger adults. Methane can contribute to the pathogenesis of constipation^{69,70}.

2. Inflammation and Aging

One of the recently recognized phenomena associated

with aging is a persistent condition of systemic inflammation as part of the age-related decline of the immune system (immunosenescence) and of the pathophysiological process of senescence (inflamm-aging)^{71,72}.

It has even been suggested that chronic activation of the immune system might be directly related to the endogenous load of molecular signals expressed by the GI microbiota. A study investigated the association between the GI microbiota composition and inflammatory status in centenarians¹⁶. The increase of interleukin (IL)-6 and IL-8 levels in peripheral blood was linked to an enrichment in Proteobacteria and a decrease in the amount of some butyrate-producing bacteria, supporting the hypothesis that age-related modifications in the GI microbiota may contribute to inflamm-aging on the one hand or be affected by systemic inflammatory status on the other¹⁶. More recently, the same authors found that age-related evolution of the GI microbiota is characterized by a reduction in the genes involved both in the metabolism of carbohydrates and in SCFA production, whereas proteolytic functions are enhanced upon aging. These alterations promote the overgrowth of pathobionts that are able to sustain and to amplify the inflammation status in older subjects⁷³.

During the advancement of age, impairment of the gut-associated lymphoid tissue (GALT) and downregulated production of strain-specific secretory IgA, together with the reduced efficiency of the innate immune defenses, such as α -defensins, antimicrobial peptides, and mucus secretion, may result in failure to control the resident microbiota, allowing an uncontrolled microbial growth on the enterocyte surface. In this context, enterocytes could engage the activation of inflammatory cytokines and chemokines, forcing dendritic cells in the underlying GALT to drive the differentiation of effector TH1, TH2, and TH17 cells that induce a strong pro-inflammatory response⁷⁴. Immunosenescence is also accompanied by a chronic, low-grade overall inflammatory condition (inflamm-aging)^{71,75}. Inflammation favors the flourishing of pathobionts, a minor component of the healthy intestinal microbiota that in an inflamed GI ecosystem can overwhelm mutualistic symbionts and support inflammation⁷⁶. A self-sustained pro-inflammatory loop that affects the entire microbial ecology of the GI tract created by pathobionts can contribute to the systemic inflammation and accelerate the process of inflamm-aging that is detrimental for host longevity.

3. Frailty

The downregulation of anti-inflammatory SCFA-producing bacteria could promote the inflamm-aging process in the intestine of the elderly. Moreover, the decline in butyrate-producing capacity may contribute to the development of degenerative diseases⁷⁷ and anorexia⁷⁸. Indeed, an augmen-

ted ability to produce SCFAs as an additional source of energy for the host is predominant in the obese phenotype, both in mice and in humans^{79,80}. Inversely, the less efficient SCFA production of the aged gut microbiota may contribute to the onset of malnutrition and sarcopenia in the elderly.

Frailty is a state of reduced physiological reserve and increased vulnerability to stress, which increases the risk of adverse outcomes such as falls, institutionalization, hospitalization, and death, due to a disorder of multiple interrelated physiological systems⁸¹. The correlation between the GI microbiota composition and frailty in older people has rarely been evaluated. van Tongeren et al.²⁸ compared the fecal microbiota composition of elderly volunteers with different grades of frailty, as assessed by the Groningen Frailty Indicator score. Fecal samples from volunteers with high frailty scores showed a significant reduction in *Lactobacillus* spp., *Bacteroides/Prevotella* spp., and *F. prausnitzii*. In contrast, the number of Enterobacteriaceae was significantly higher in the highly frail older subjects. More recently, Claesson et al.⁴³ found an association between the microbiota composition in the elderly and diet, inflammatory status, and clinical parameters. Moreover, they included a series of functional, cognitive, and nutritional measurements, most of which are part of the Comprehensive Geriatric Assessment⁸¹, including the Barthel Motility Index, Functional Independence Measure, Mini-Mental Status Examination, Mini Nutritional Assessment, body mass index, and calf circumference. Loss of the community-associated microbiota correlated with increased impairment in the above-mentioned functional, cognitive, and nutritional parameters and supported a relationship between diet, the microbiota, and multidimensional health status. This indicated the diet-driven microbiota changes can have an impact on the decline in health with aging.

4. Metabolic Outcome and CNS

The microbiota in the GI tract is itself a source of metabolites and has an influence on the bioavailability of amino acids. The GI microbiota has been proposed to have an impact on adipose tissue and skeletal muscle energy metabolism, liver fat metabolism and hepatic steatosis, atherosclerosis and cardiovascular diseases, and enteroendocrine metabolism⁸²⁻⁸⁴. Of note is that SCFAs play a pivotal role in modulating the host energy metabolism. Given the tendency toward decreased production in SCFAs in the elderly, there would be a consequent imbalance in energy metabolism.

The microbiome-gut-brain axis, a 2-way communication that incorporates neuronal, hormonal, nutritional, and immunological signals between the CNS and the GI system⁸⁵, has been the basis for understanding the role of the GI microbiome in CNS diseases. Recent studies have provided evidence that the importance of the GI microbiome in a variety of

CNS disorders including multiple sclerosis, Guillain-Barré syndrome, Parkinson disease, Alzheimer disease, and neuropsychiatric disorders (i.e., autism, depression, and anxiety)^{86,87}. A significantly increased brain content of two phenolic acids produced by the GI microbiota after administration of grape seed polyphenol extract has been observed in a rat model. These phenolic acids potentially hamper the assembly of β -amyloid peptides into neurotoxic β -amyloid. This suggests a potential role of the GI microbiota in protecting against neurodegenerative disorders⁸⁸.

5. GI Malignancy

A pro-inflammatory dysbiosis, together with decreased butyrate production in the intestine, has also been linked to an increased risk of colorectal cancer (CRC)⁸⁹⁻⁹¹. Metabolic profiling studies using human fecal water extracts demonstrated a significant decrease of SCFA content in CRC^{90,91}. The incidence of CRC increases in aged people, with approximately 50% of the western population developing colorectal polyps at the age of 70 and 5% of these polyps progressing to cancer⁹². The connection between CRC and aging raises the question of whether the age-related dysbiosis of the intestinal microbiota may be involved in CRC development. Colonic bacteria can affect the neoplastic process by inducing mucosal inflammation in the GI tract⁸⁹. Then, the chronic inflammation can support carcinogenesis by inducing gene mutations that lead to the loss of antiapoptotic and antiangiogenic properties. In particular, nuclear factor- κ B is a key factor providing a mechanistic link between inflammation and CRC⁹³, and its activation by toll-like receptor ligands from intestinal microorganisms has been evaluated⁹⁴. Therefore, sustaining inflammation in the GI tract by an aged intestinal microbiota may support CRC onset and progression.

Furthermore, the impairment of the barrier function of the aging gut microbiota could accelerate tumorigenesis by permitting persistent GI colonization by toxigenic bacterial strains. Certain bacterial toxins, such as toxin from toxigenic *Bacteroides fragilis* strains, colibactin, cytotoxin necrotizing factor 1, and cytolethal distending toxin from toxigenic *Escherichia coli* strains, can perturb the eukaryotic cellular signaling linked to cell cycle regulation and growth control, or directly damage DNA⁶. Besides toxins, lipopolysaccharides are also associated with metastatic colorectal tumor growth⁹⁵. A better understanding of these pro-carcinogenic mechanisms may represent a crucial point in planning preventive and therapeutic strategies for CRC, which may include the modulation of the gut microbiota by probiotics, prebiotics, and/or antibiotics, with the aim of favoring bacterial species able to exert anti-carcinogenic activity.

Strong positive correlations were demonstrated between the quantification of each candidate by our quantitative polymere-

rase chain reaction assays and metagenomics approach ($r=0.801-0.934$, all $p<0.0001$). *Fusobacterium nucleatum* was significantly more abundant in CRC than controls ($p<0.0001$)⁹⁶. Resident microbes can induce inflammation, leading to cell proliferation and altered stem cell dynamics, which can lead to alterations in DNA integrity and immune regulation and promote carcinogenesis. Interestingly, a study in human patients and in rodent models of cancer have identified alterations in the microbiota of the stomach, esophagus, and colon that increase the risk for malignancy⁹⁷.

CONCLUSIONS AND FUTURE PERSPECTIVES

The bowel encompasses a diverse community where complex interactions between the body and the microbiota occur. There is a growing body of evidence that changes in the gut microbiota composition may be related to numerous age-related physiological processes.

Dietary habits, reduced physical activity, and the use of antibiotics, NSAIDs, and proton pump inhibitors can change the microbiota profile. However, there is no consensus about the definition of old-age specific gut microbiota profile due to the high interindividual variability, differences in diet and lifestyle, and the unclear definition of the term “elderly.”

Nevertheless, it has been relatively consistently reported that there is reduced diversity in the microbiota in the elderly compared with younger contemporaries and reduced production in SCFAs. The ability of several members of the gut microbial community to produce SCFAs is an essential feature of a healthy gut ecosystem. Age-related microbiota depletion in SCFA producers may compromise the integrity of the epithelial barrier. Such a weakened gut epithelium allows the passage of whole bacterial cells and their products and disrupts immunological tolerance.

According to the literature, dysbiosis in the elderly could be associated with inflammation, frailty, GI malignancy, metabolic disease, and even CNS disease.

However, whether these changes in the gut microbiota profile are the cause or the effect of aging is still an open question. Therefore, more comprehensive evaluation including diet-microbiota-health interactions must be evaluated in the broader context of the genetic and lifestyle changes that accompany aging. Currently, prevailing internet of things (IoT) and big data collection technology may facilitate the evaluation of associations between microbiota composition and lifestyle or diet.

If a healthy microbiota composition is established, manipulation of the gut microbiota composition through the use of pro- or prebiotics and early detection of illness using regular screenings of individual microbiome profiles may be a strategy for healthy aging. This could be one of the approaches for personalized medicine.

Conflicts of Interest Disclosures: The researchers claim no conflicts of interest.

Acknowledgments

This work was supported by a National Research Foundation (NRF) of Korea grant for the Global Core Research Center (GCRC) funded by the Korea government (MSIP) (No. 2011-0030001).

REFERENCES

1. Statistics Korea. 2015 Elderly statistics [Internet]. Daejeon: Statistics Korea; c2015 [cited 2016 Oct 19]. Available from: http://kostat.go.kr/portal/korea/kor_nw/2/1/index.board?bmode=read&caSeq=348565.
2. Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature* 2013; 498:99-103.
3. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010;464:59-65.
4. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. *Nature* 2009;457:480-4.
5. Lagier JC, Hugon P, Khelaifia S, Fournier PE, La Scola B, Raoult D. The rebirth of culture in microbiology through the example of culturomics to study human gut microbiota. *Clin Microbiol Rev* 2015;28:237-64.
6. Biagi E, Candela M, Turrone S, Garagnani P, Franceschi C, Brigidi P. Ageing and gut microbes: perspectives for health maintenance and longevity. *Pharmacol Res* 2013;69:11-20.
7. Collado MC, Rautava S, Aakko J, Isolauri E, Salminen S. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. *Sci Rep* 2016; 6:23129.
8. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. *Nat Rev Immunol* 2010;10:159-69.
9. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, et al. Succession of microbial consortia in the developing infant gut microbiome. *Proc Natl Acad Sci U S A* 2011;108 Suppl 1:4578-85.
10. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. *PLoS Biol* 2007;5:e177.
11. Turrone F, Peano C, Pass DA, Foroni E, Severgnini M, Claesson MJ, et al. Diversity of bifidobacteria within the infant gut microbiota. *PLoS One* 2012;7:e36957.
12. Voreades N, Kozil A, Weir TL. Diet and the development of the human intestinal microbiome. *Front Microbiol* 2014;5:494.
13. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. *Nature* 2012;486:222-7.
14. Human Microbiome Project Consortium. Structure, function

- and diversity of the healthy human microbiome. *Nature* 2012; 486:207-14.
15. Mihajlovski A, Doré J, Levenez F, Alric M, Brugère JF. Molecular evaluation of the human gut methanogenic archaeal microbiota reveals an age-associated increase of the diversity. *Environ Microbiol Rep* 2010;2:272-80.
 16. Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS One* 2010;5: e10667.
 17. Biagi E, Candela M, Fairweather-Tait S, Franceschi C, Brigidi P. Aging of the human metaorganism: the microbial counterpart. *Age (Dordr)* 2012;34:247-67.
 18. Duncan SH, Flint HJ. Probiotics and prebiotics and health in ageing populations. *Maturitas* 2013;75:44-50.
 19. Sim K, Cox MJ, Wopereis H, Martin R, Knol J, Li MS, et al. Improved detection of bifidobacteria with optimised 16S rRNA-gene based pyrosequencing. *PLoS One* 2012;7:e32543.
 20. Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao JZ, et al. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. *BMC Microbiol* 2016;16:90.
 21. Hayashi H, Sakamoto M, Kitahara M, Benno Y. Molecular analysis of fecal microbiota in elderly individuals using 16S rDNA library and T-RFLP. *Microbiol Immunol* 2003;47:557-70.
 22. Mäkituokko H, Tiihonen K, Tynkkynen S, Paulin L, Rautonen N. The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition. *Br J Nutr* 2010; 103:227-34.
 23. Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T, et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. *Appl Environ Microbiol* 2006;72:1027- 33.
 24. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci U S A* 2011;108 Suppl 1:4586-91.
 25. Tiihonen K, Tynkkynen S, Ouwehand A, Ahlroos T, Rautonen N. The effect of ageing with and without non-steroidal anti-inflammatory drugs on gastrointestinal microbiology and immunology. *Br J Nutr* 2008;100:130-7.
 26. Bartosch S, Fite A, Macfarlane GT, McMurdo ME. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. *Appl Environ Microbiol* 2004;70:3575-81.
 27. Zwielerhner J, Liszt K, Handschur M, Lassl C, Lapin A, Haslberger AG. Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in fecal population sizes and diversity of Bacteroides, bifidobacteria and Clostridium cluster IV in institutionalized elderly. *Exp Gerontol* 2009;44:440-6.
 28. van Tongeren SP, Slaets JP, Harmsen HJ, Welling GW. Fecal microbiota composition and frailty. *Appl Environ Microbiol* 2005;71:6438-42.
 29. Gueimonde M, Ouwehand A, Pitkälä K, Strandberg T, Finne-Soveri H, Salminen S. Fecal Bifidobacterium levels in elderly nursing home patients are levels as expected? *Bioscience Microflora* 2010;29:111-3.
 30. Salazar N, López P, Valdés L, Margolles A, Suárez A, Patterson AM, et al. Microbial targets for the development of functional foods accordingly with nutritional and immune parameters altered in the elderly. *J Am Coll Nutr* 2013;32:399-406.
 31. Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Doré J, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. *BMC Microbiol* 2009;9:123.
 32. Rajilić-Stojanović M, Heilig HG, Molenaar D, Kajander K, Surakka A, Smidt H, et al. Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. *Environ Microbiol* 2009;11: 1736-51.
 33. Pédrón T, Sansonetti P. Commensals, bacterial pathogens and intestinal inflammation: an intriguing ménage à trois. *Cell Host Microbe* 2008;3:344-7.
 34. Mello AM, Paroni G, Daragjati J, Pilotto A. Gastrointestinal Microbiota and Their Contribution to Healthy Aging. *Dig Dis* 2016;34:194-201.
 35. Zhao L, Qiao X, Zhu J, Zhang X, Jiang J, Hao Y, et al. Correlations of fecal bacterial communities with age and living region for the elderly living in Bama, Guangxi, China. *J Microbiol* 2011; 49:186-92.
 36. Drago L, Toscano M, Rodighiero V, De Vecchi E, Mogna G. Cultivable and pyrosequenced fecal microflora in centenarians and young subjects. *J Clin Gastroenterol* 2012;46 Suppl:S81-4.
 37. Wang F, Huang G, Cai D, Li D, Liang X, Yu T, et al. Qualitative and semiquantitative analysis of fecal bifidobacterium species in Centenarians living in Bama, Guangxi, China. *Curr Microbiol* 2015;71:143-9.
 38. Doty RL, Shaman P, Applebaum SL, Giberson R, Siksorski L, Rosenberg L. Smell identification ability: changes with age. *Science* 1984;226:1441-3.
 39. Newton JP, Yemm R, Abel RW, Menhinick S. Changes in human jaw muscles with age and dental state. *Gerodontology* 1993;10:16-22.
 40. Lovat LB. Age related changes in gut physiology and nutritional status. *Gut* 1996;38:306-9.
 41. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. *ISME J* 2011;5:220-30.
 42. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science* 2011;334:105-8.
 43. Claesson MJ, Jeffery IB, Conde S, Power SE, O'Connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. *Nature* 2012;488:178-84.
 44. Thomas F, Hehemann JH, Rebuffet E, Czejek M, Michel G. Environmental and gut bacteroidetes: the food connection. *Front Microbiol* 2011;2:93.
 45. Camilleri M, Lee JS, Viramontes B, Bharucha AE, Tangalos EG. Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people. *J Am Geriatr Soc* 2000;48:1142-50.
 46. Hamer HM, De Preter V, Windey K, Verbeke K. Functional analysis of colonic bacterial metabolism: relevant to health? *Am J Physiol Gastrointest Liver Physiol* 2012;302:G1-9.
 47. Maloy KJ. The Interleukin-23/Interleukin-17 axis in intestinal

- inflammation. *J Intern Med* 2008;263:584-90.
48. Cotter PD, Stanton C, Ross RP, Hill C. The impact of antibiotics on the gut microbiota as revealed by high throughput DNA sequencing. *Discov Med* 2012;13:193-9.
 49. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. *Microbiology* 2010;156(Pt 11):3216-23.
 50. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. *J Clin Microbiol* 2004;42:1203-6.
 51. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. *Trends Microbiol* 2004;12:412-6.
 52. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc Natl Acad Sci U S A* 2011;108 Suppl 1:4554-61.
 53. O'Sullivan O, Coakley M, Lakshminarayanan B, Conde S, Claesson MJ, Cusack S, et al. Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy. *J Antimicrob Chemother* 2013;68:214-21.
 54. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. *Gut* 2016;65:740-8.
 55. Shin CM, Kim N, Kim YS, Nam RH, Park JH, Lee DH, et al. Impact of long-term proton pump inhibitor therapy on gut microbiota in f344 rats: pilot study. *Gut Liver* 2016;10:896-901.
 56. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. *Nat Rev Microbiol* 2009;7:526-36.
 57. Rea MC, O'Sullivan O, Shanahan F, O'Toole PW, Stanton C, Ross RP, et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. *J Clin Microbiol* 2012;50:867-75.
 58. Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent clostridium difficile infection. *J Clin Gastroenterol* 2011;45 Suppl:S159-67.
 59. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. *FEMS Microbiol Lett* 2009;294:1-8.
 60. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. *Appl Environ Microbiol* 2000;66:1654-61.
 61. Barcelo A, Claustre J, Moro F, Chayvialle JA, Cuber JC, Plaisancié P. Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. *Gut* 2000;46:218-24.
 62. Petersson J, Schreiber O, Hansson GC, Gendler SJ, Velcich A, Lundberg JO, et al. Importance and regulation of the colonic mucus barrier in a mouse model of colitis. *Am J Physiol Gastrointest Liver Physiol* 2011;300:G327-33.
 63. Suzuki T, Yoshida S, Hara H. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. *Br J Nutr* 2008;100:297-305.
 64. Hippe B, Zwielehner J, Liszt K, Lassl C, Unger F, Haslberger AG. Quantification of butyryl CoA: acetate CoA-transferase genes reveals different butyrate production capacity in individuals according to diet and age. *FEMS Microbiol Lett* 2011;316:130-5.
 65. Macia L, Thorburn AN, Binge LC, Marino E, Rogers KE, Maslowski KM, et al. Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. *Immunol Rev* 2012;245:164-76.
 66. Schiffrin EJ, Morley JE, Donnet-Hughes A, Guigoz Y. The inflammatory status of the elderly: the intestinal contribution. *Mutat Res* 2010;690:50-6.
 67. Pimentel M, Lin HC, Enayati P, van den Burg B, Lee HR, Chen JH, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. *Am J Physiol Gastrointest Liver Physiol* 2006;290:G1089-95.
 68. Lewis SJ, Heaton KW. Increasing butyrate concentration in the distal colon by accelerating intestinal transit. *Gut* 1997;41:245-51.
 69. Parthasarathy G, Chen J, Chen X, Chia N, O'Connor HM, Wolf PG, et al. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. *Gastroenterology* 2016;150:367-79.e1.
 70. Ghoshal UC, Srivastava D, Verma A, Misra A. Slow transit constipation associated with excess methane production and its improvement following rifaximin therapy: a case report. *J Neurogastroenterol Motil* 2011;17:185-8.
 71. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. *Mech Ageing Dev* 2007;128:92-105.
 72. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci* 2000;908:244-54.
 73. Rampelli S, Candela M, Turroni S, Biagi E, Collino S, Franceschi C, et al. Functional metagenomic profiling of intestinal microbiome in extreme ageing. *Ageing (Albany NY)* 2013;5:902-12.
 74. Maynard CL, Weaver CT. Intestinal effector T cells in health and disease. *Immunity* 2009;31:389-400.
 75. Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G. Aging of the immune system as a prognostic factor for human longevity. *Physiology (Bethesda)* 2008;23:64-74.
 76. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol* 2009;9:313-23.
 77. Guigoz Y, Doré J, Schiffrin EJ. The inflammatory status of old age can be nurtured from the intestinal environment. *Curr Opin Clin Nutr Metab Care* 2008;11:13-20.
 78. Donini LM, Savina C, Cannella C. Nutritional interventions in the anorexia of aging. *J Nutr Health Aging* 2010;14:494-6.
 79. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006;444:1027-31.
 80. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature* 2006;444:1022-3.
 81. Ferrucci L, Giallauria F, Schlessinger D. Mapping the road to resilience: novel math for the study of frailty. *Mech Ageing Dev* 2008;129:677-9.

82. Burcelin R, Serino M, Chabo C, Blasco-Baque V, Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. *Acta Diabetol* 2011;48:257-73.
83. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. *Science* 2012;336:1262-7.
84. Choi Y, Kwon Y, Kim DK, Jeon J, Jang SC, Wang T, et al. Gut microbe-derived extracellular vesicles induce insulin resistance, thereby impairing glucose metabolism in skeletal muscle. *Sci Rep* 2015;5:15878.
85. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. *Nat Rev Microbiol* 2012; 10:735-42.
86. Luna RA, Foster JA. Gut brain axis: diet microbiota interactions and implications for modulation of anxiety and depression. *Curr Opin Biotechnol* 2015;32:35-41.
87. Tillisch K. The effects of gut microbiota on CNS function in humans. *Gut Microbes* 2014;5:404-10.
88. Wang D, Ho L, Faith J, Ono K, Janle EM, Lachcik PJ, et al. Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease β -amyloid oligomerization. *Mol Nutr Food Res* 2015;59: 1025-40.
89. Candela M, Guidotti M, Fabbri A, Brigidi P, Franceschi C, Fiorentini C. Human intestinal microbiota: cross-talk with the host and its potential role in colorectal cancer. *Crit Rev Microbiol* 2011;37:1-14.
90. Monleón D, Morales JM, Barrasa A, López JA, Vázquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. *NMR Biomed* 2009;22:342-8.
91. Holmes E, Li JV, Athanasiou T, Ashrafian H, Nicholson JK. Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. *Trends Microbiol* 2011;19: 349-59.
92. Boyle P, Ferlay J. Mortality and survival in breast and colorectal cancer. *Nat Clin Pract Oncol* 2005;2:424-5.
93. Kraus S, Arber N. Inflammation and colorectal cancer. *Curr Opin Pharmacol* 2009;9:405-10.
94. Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J, et al. ERK activation drives intestinal tumorigenesis in *Apc* (min/+) mice. *Nat Med* 2010;16:665-70.
95. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF- κ B-dependent activation of the urokinase plasminogen activator system. *Br J Cancer* 2009;100: 1589-602.
96. Liang JQ, Chiu J, Chen Y, Huang Y, Higashimori A, Fang JY, et al. Fecal bacteria act as novel biomarkers for non-invasive diagnosis of colorectal cancer. *Clin Cancer Res* 2016 Oct 3 [Epub]. <https://doi.org/10.1158/1078-0432.CCR-16-1599>.
97. Wroblewski LE, Peek RM Jr, Coburn LA. The role of the microbiome in gastrointestinal cancer. *Gastroenterol Clin North Am* 2016;45:543-56.